| Literature DB >> 25533624 |
Jon Feldman1,2, Limor Appelbaum3, Mordechay Sela4, Ninel Voskoboinik5, Sarit Kadouri6, Jeffrey Weinberger7, Itzhak Orion8, Amichay Meirovitz9.
Abstract
PURPOSE/Entities:
Mesh:
Year: 2014 PMID: 25533624 PMCID: PMC4299482 DOI: 10.1186/s13014-014-0271-x
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Figure 1Patient with lower lip T2 SCC during treatment: (A) pre treatment lesion, (B) mold used to distance the lip for external beam treatment, (C) the interstitial insertions, (D) CMS with embedded catheters, (E + F) the patient during treatment, (G + H) cosmetic and functional results after 4 years. SCC = Squamous Cell Carcinoma CMS = Customized Mold Sandwich.
Figure 2Comparison between the "sandwich" technique and "classic" interstitial only technique. Reconstructive image of the interstitial and mold catheters in relation to the lip and the mandible (A). Comparison of the DVH between the interstitial catheters only (B) and the CMS (C) techniques at the same level. Note the invagination of the dose to the mandible in the “classic” interstitial catheters technique. Coverage by the lip catheters (D,F) compared to the CMS (E,G) from two different angles. The DVH of the target in the interstitial catheters only (H) and the CMS (I) techniques. Note that the high dose regions without the mold are more than twice that as with the mold. DVH = Dose Volume Histogram CMS = Customized Mold Sandwich.
Patient characteristics
|
|
|
|---|---|
| Age (years) | |
| Mean | 58 |
| Range | 36-81 |
| Sex | |
| Male | 7 (100%) |
| Female | 0 (0%) |
| Tumor site | |
| Upper lip | 1 (14%) |
| Lower lip | 6 (86%) |
| T stage | |
| T2 | 7 (100%) |
| Tumor size (cm) | |
| Mean | |
| Range | 2-3 |
| Tumor grade | |
| Well differentiated | 5 |
| Moderately differentiated | 1 |
| Ulcerated | 1 |
| Prior wedge resection | |
| (recurrence) | 1 |
| cm = centimeters |
The plan characteristic reported according to ICRU 58
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Patient 1 | Treated Volume | 7.39 | 95.48% | 7.29 | 94.19% |
| CTV-7.74cc | High-dose region | 4.53 | 58.53% | 5.91 | 76.36% |
| Low-dose region | 0.08 | 1.03% | 0.25 | 3.23% | |
| Patient 2 | Treated Volume | 6.49 | 92.71% | 6.37 | 91.00% |
| CTV-7.00cc | High-dose region | 3.7 | 52.86% | 4.17 | 59.57% |
| Low-dose region | 0.33 | 4.71% | 0.29 | 4.14% | |
| Patient 3 | Treated Volume | 2.43 | 92.40% | 2.35 | 89.35% |
| CTV-2.63cc | High-dose region | 1.55 | 58.94% | 1.57 | 59.70% |
| Low-dose region | 0.07 | 2.66% | 0.11 | 4.18% | |
| Patient 4 | Treated Volume | 8.75 | 97.01% | 8.56 | 94.90% |
| CTV-9.02cc | High-dose region | 4.92 | 54.55% | 5.6 | 62.08% |
| Low-dose region | 0.11 | 1.22% | 0.2 | 2.22% | |
| Patient 5 | Treated Volume | 9.88 | 88.53% | 9.63 | 86.29% |
| CTV-11.16cc | High-dose region | 5.92 | 53.05% | 7.01 | 62.81% |
| Low-dose region | 0.78 | 6.99% | 1.15 | 10.30% | |
| Patient 6 | Treated Volume | 8.64 | 93.81% | 8.28 | 89.90% |
| CTV-9.21cc | High-dose region | 4.96 | 53.85% | 5.79 | 62.87% |
| Low-dose region | 0.2 | 2.17% | 0.48 | 5.21% | |
| Patient 7 | Treated Volume | 17.81 | 89.01% | 17.36 | 86.76% |
| CTV-20.01cc | High-dose region | 6.31 | 31.53% | 9.3 | 46.48% |
| Low-dose region | 1.41 | 7.05% | 1.19 | 5.95% | |
Calculation of the coverage of the target using the ICRU 58 guidelines for the “sandwich” technique and interstitial catheter only ("classic") for each individual patient.
The Conformal Index (COIN)
|
|
| |
|---|---|---|
| Patient 1 | 0.930 | 0.784 |
| Patient 2 | 0.927 | 0.910 |
| Patient 3 | 0.924 | 0.894 |
| Patient 4 | 0.970 | 0.949 |
| Patient 5 | 0.885 | 0.863 |
| Patient 6 | 0.938 | 0.887 |
| Patient 7 | 0.884 | 0.868 |
Calculation of the Conformal index (COIN) for the “sandwich” technique and interstitial catheter only for each individual patient.
Dose, technique and outcomes
|
|
|
|
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||||
| 1. | Lower lip | T2 | none | 50 Gy | 2 Gy/fr | 30 Gy | 2 Gy BID | 2 | 2 | 47 mo | 5 | 5 |
| 2. | Upper lip | T2 | none | 50 Gy | 2 Gy/fr | 30 Gy | 3 Gy BID | 3 | 4 | 37 mo | 5 | 5 |
| 3. | Lower lip | T2 | none | none | 42 Gy | 3 Gy BID | 1 | 2 | 32 mo | 5 | 5 | |
| 4. | Lower lip | T2 | none | 50 Gy | 2 Gy/fr | 18 Gy | 3 Gy BID | 2 | 3 | 33 mo | 5 | 5 |
| 5. | Lower lip | T2 | Surgery, close margins | 44 Gy | 2 Gy/fr | 25 Gy | 2.5 Gy BID | 2 | 2 | 29 mo | 5 | 5 |
| 6. | Lower lip | T2 | none | none | 42 Gy | 3 Gy BID | 4 | 3 | 38 mo | 5 | 5 | |
| 7. | Lower lip recurrence | T2 post op | Wedge resection | none | 39 Gy | 3 Gy BID | 2 | 1 | 29 mo | 5 | 5 | |
EBRT = External Beam Radiation Therapy, Gy = Gray, fr = fraction, BID = Twice daily, mo = month, #=number of.